Baker McKenzie has successfully represented Berlin-Chemie AG — the maker of the Nimesil anti-inflammatory drug — in its trademark challenge to the Nimesin brand.
According to Baker McKenzie, “on July 15, 2020, the Appellate Commercial Court upheld the decision of the Commercial Court of the City of Kyiv in relation to the cancellation of the Nimesin trademark registrations granted by the Ministry of Economic Development, Trade and Agriculture of Ukraine, the cancellation of the marketing authorization for Nimesin medicine issued by the Ministry of Healthcare of Ukraine for Organosin Life Sciences Private Ltd. (India), the prohibition of Evertogen Life Sciences Limited from manufacturing Nimesin medicine, and the prohibition of Organosin Ltd. from selling and importing Nimesin medicine. Upholding the decision of the Commercial Court of the City of Kyiv, the Appellate Commercial Court rejected both counterclaims by Organosin Ltd. and Evertogen Life Sciences Limited."
Baker McKenzie’s team was led by Counsel Oleksiy Stolyarenko and included Associates Anton Kapitonenko and Khrystyna Nykerui.
